RxDoctor Payments Data

Chaudry Mushtaq, MD

Hematology & Oncology · Columbia, SCNPI 1942281399

Payments from drug & device makers

$11,916in general payments, 2019–2025

Across 588 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Merck$724
  • Johnson & Johnson$648
  • Pfizer$606
  • E.r. Squibb & Sons, L.L.C.$554
  • Bristol Myers Squibb$544
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$11,78999%
  • Education$1271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis50$1,138
Merck31$724
Johnson & Johnson(2 entities)29$648
Pfizer37$606
E.r. Squibb & Sons, L.L.C.41$554
Bristol Myers Squibb30$544
AstraZeneca(2 entities)27$479
Takeda Pharmaceuticals U.S.A., Inc.26$418
Lilly USA, LLC18$385
Incyte Corporation13$345
Daiichi Sankyo Inc.13$325
Genentech USA, Inc.16$313
Amgen11$313
Astellas Pharma US Inc14$271
GSK11$269
Heron Therapeutics, Inc.1$254
Sanofi8$209
Seagen Inc.12$190
Eagle Pharmaceuticals, Inc.4$187
Rigel Pharmaceuticals, Inc.8$186
Jazz Pharmaceuticals Inc.11$183
Puma Biotechnology, Inc.9$172
ADC Therapeutics America, Inc.9$168
Gilead9$165
Bayer10$158
AVEO Pharmaceuticals, Inc.7$154
Array Biopharma Inc11$152
EMD Serono, Inc.6$151
Eisai Inc.7$150
Taiho Oncology, Inc.7$129
Exelixis Inc.8$118
AbbVie6$116
Regeneron Healthcare Solutions, Inc.5$110
Immunocore Limited4$95
Servier Pharmaceuticals LLC4$93
Sobi, Inc5$87
Spectrum Pharmaceuticals Inc.4$84
Beigene USA, Inc.5$83
Ipsen Biopharmaceuticals, Inc4$80
Boehringer Ingelheim3$78
Mirati Therapeutics, Inc.3$72
Kyowa Kirin, Inc.4$66
Deciphera Pharmaceuticals Inc.2$64
G1 Therapeutics, Inc.2$63
Karyopharm Therapeutics Inc.4$63
Beone Medicines USA, Inc.3$56
Tersera Therapeutics LLC3$53
Genmab U.S., Inc.2$53
Pharmaessentia USA Corporation2$53
Macrogenics, Inc.2$47
Morphosys, US Inc.3$46
Blueprint Medicines Corporation3$39
Sumitomo Pharma America, Inc.2$35
CTI Biopharma Corp.2$34
Aurobindo Pharma USA, Inc.2$34
Springworks Therapeutics, Inc.2$30
Pharmacyclics LLC, An Abbvie Company2$27
Helsinn Therapeutics (U.S.), Inc.2$26
Genentech, Inc.1$26
Stemline Therapeutics Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,916 in reported general payments places this provider in the 55th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$5,260,506
Medicare patients
968
Services billed
297,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Exemestane15$1,146
Ondansetron OdtOndansetron38$1,018
Letrozole23$731
Dexamethasone31$517
Prochlorperazine Maleate33$271
Potassium Chloride18$148

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →